Medication info

Linagliptin Duo Tablet 2.5/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Jinyang Pharmaceutical Co., Ltd.
Appearance
Bright orange oval film-coated tablet
Packaging
60 tablets/box [(10 tablets/PTPX6)]
Approval status
Expired

MFDS item code 202003652 · Approved 2020.05.19

This product's status changed to Expired on 2025.05.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with diabetes drug therapy and whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medication is 2.5/500 mg twice daily, 1 tablet per dose; the dose may be increased to 2.5/1000 mg twice daily, 1 tablet per dose. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medication should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately.

Ingredients

Manufacturer
Jinyang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes mellitus

  • Type 2 Diabetes
  • Blood Sugar Control Disorder
View approved original text

This medication is used as a treatment to improve blood sugar control in adult patients with type 2 diabetes. It is administered when adequate blood sugar control is not possible with diet and exercise alone. It can also be added to existing treatments with metformin or other diabetes medications when blood sugar is not sufficiently controlled. In various combination therapies, this medication improves blood sugar control ability and can be used together with insulin. Even in cases with complex treatment experiences, this medication can effectively aid in blood sugar control.

How to take

Adult dose

The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with diabetes drug therapy and whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medication is 2.5/500 mg twice daily, 1 tablet per dose; the dose may be increased to 2.5/1000 mg twice daily, 1 tablet per dose. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medication should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately.

Precautions

This medication is designed to assist in blood sugar control and one of its main ingredients is metformin hydrochloride. Metformin hydrochloride can cause a rare but serious side effect called lactic acidosis, so caution is necessary. This medication should not be administered to certain patients. For example, patients allergic to this medication or its components, patients with type 1 diabetes, lactic acidosis or diabetic ketoacidosis, patients with severe kidney dysfunction, patients with acute infections or severe dehydration can be at risk when taking this medication. Additionally, patients with poor liver function, those with alcoholism or malnutrition, and pregnant or breastfeeding women are advised against taking this medication. Caution should be taken with hypoglycemia while taking this medication, especially when combined with other glucose-lowering agents or insulin. Symptoms of hypoglycemia may include dizziness, cold sweat, severe fatigue, etc. To reduce the risk of lactic acidosis, kidney function should be monitored regularly, and if renal function declines, this medication should be discontinued or adjusted. In situations where kidney function deteriorates rapidly, immediate consultation with healthcare professionals is required. Patients with weakened heart function should also be observant when taking this medication. Moreover, if iodine-based contrast agents are administered during radiological examinations, this medication should be temporarily discontinued. This medication may trigger acute pancreatitis and conditions such as blistering dermatitis, so if severe abdominal pain or blisters on the skin occur while taking it, immediate consultation with a doctor is necessary. It can reduce vitamin B12 levels, so patients taking it for long periods are advised to regularly check vitamin B12 levels. This medication may interact with other drugs, so if other medications are being taken, it is essential to inform healthcare providers, particularly when co-administering drugs that may affect kidney function. Pregnant women or those planning pregnancy are recommended not to take this medication, and breastfeeding women should also avoid taking it. It is not recommended for children under 10 years old and adolescents aged 10 to 17, as safety and efficacy have not been established for this age group. Elderly patients may have decreased kidney function, so it is advisable to regularly monitor kidney function before and during the use of this medication and to administer it at the lowest possible dose. In the event of an overdose, there is a risk of lactic acidosis, and patients should visit a medical institution immediately for appropriate treatment. This medication should be stored away from moisture and direct sunlight and kept out of reach of children.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 reduction and deficiency
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 109 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular dermatitis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • itching
  • hypertension
  • benign prostatic hyperplasia
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • cavities
  • enteritis
  • gastritis
  • dizziness
  • drowsiness
  • chest discomfort
  • asthenia
  • pain
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • goiter
  • confusion
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a sealed container. The recommended storage temperature is between 1 and 30 degrees Celsius to maintain the medication's efficacy for a longer period.

Appearance and packaging

Appearance

Bright orange oval film-coated tablet

Package unit

60 tablets/box [(10 tablets/PTPX6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.